Adoptive cell therapy for Melanoma using tumour infiltrating lymphocytes: John Bridgeman

22 vistas
administrator
administrator
07/30/23

A look at the use of TIL in Melanoma and future TIL engineering strategies. John Bridgeman is the Director of Cell Therapy Research at Immetacyte Ltd

  • categoría

Mostrar más

0 Comentarios Ordenar por

No se encontraron comentarios

Comentarios de Facebook

Hasta la próxima